CD274 and head and neck squamous cell carcinoma: While survival in this population remained relatively unchanged over the past several decades, immune checkpoint blockade has revolutionized therapy for HNSCC patients, with up to 20% of recurrent or metastatic patients responding to immunotherapies targeting the PD1:PDL1 interaction [3].